Moderna Stock News

Fauci''s Finished Authored by James Rickards via DailyReckoning.com, In a little under an hour, Joe Biden is expected to address the nation about the new Omicron variant of the virus. An aide claims the administration is prepared for the rising case levels and that Biden will explain how it will respond to this challenge. The Omicron variant is highly contagious. Some models, along with data from Europe, suggest the number of cases could potentially double every two days. Of course, you cant really trust models, but this variant is spreading rapidly. The good news is that it doesnt appear to be particularly dangerous. Symptoms are generally described as those of a mild cold. But you can expect Biden to dial up the fear tomorrow. Hes probably going to try to shame the unvaccinated and warn about a dark winter ahead because of their refusal to take the jabs. For the fully vaccinated, hes going to tell them to get the booster. Well have to see what else he has in store, but you can be sure it wont involve telling everyone to take hydroxychloroquine or ivermectin if they start showing symptoms.

European stocks closed on a strong note, rebounding from the previous session''s losses, as some encouraging earnings updates and a report from Moderna Inc. saying the laboratory test of a booster dose of its Covid-19 vaccine had shown itself to be effective against the Omicron variant.

Charity organization and Moderna shareholder Oxfam America said on Tuesday it filed a whistleblower complaint with the Securities and Exchange Commission (SEC) against the biotechnology company over i

Results from Modernas early trial to build an Omicron-specific booster dose have shown that the prototype of the authorised booster vaccine is 37 percent effective against Omicron. A higher formulated dose was found to be approximately 83 percent more efficacious compared with pre-boost levels and better at increasing neutralising antibodies levels. The biotechnology company in []

The SP500 index is slightly higher today on the back of Moderna''s booster shot news, and earnings from Nike and Micron.

The biotech firm says its booster shot gives good protection against Omicron.

Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant but for now is focussing on a booster dose of its current Covid vaccine.

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MU, CIT, MRNA, AVGO, and KO. Full story available on Benzinga.com

Moderna Inc. (NASDAQ:MRNA) traded at $276.38 at close of the session on Monday, 12/20/21, made a downward move of -6.25% on its previous days price. Looking at the stock we see that its previous close was $294.80 and the beta (5Y monthly) reads 1.49 with the days price range being $275.12 $321.305. The company Are Investors Keen On Selling Holdings In Moderna Inc. (NASDAQ: MRNA)? Read More »

Moderna (MRNA) disclosed that a booster shot of its coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant.

It''s based on older technology than Pfizer or Moderna

PARIS: Giving a full dose of Moderna''s COVID-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections, the company said on Monday (Dec 20). The lab study measured the levels of Omicron-neutralising antibodies in

Moderna shares surged higher in pre-market trading after the drugmaker said booster shots of its coronavirus vaccine induced a big jump in antibodies that can fight against the Omicron variant.

The post Moderna says booster of its Covid vaccine increases protection appeared on BitcoinEthereumNews.com . Empty bottles of Moderna Covid-19 vaccine are pictured in a vaccination center in Garlan, western France, on December 13, 2021. FRED TANNEAU | AFP | Getty Images Moderna announced Monday